The MHRA’s new 14-Day Phase I Pilot is designed to speed up regulatory assessment for eligible, lower-risk Phase I healthy volunteer studies, with the aim of reducing the MHRA’s first review timeline from 30 to 14 calendar days by the end of 2026.
For global sponsors deciding where to place Phase I studies, regulatory speed, predictability and clarity matter. The UK is competing with established early phase markets including the US, Australia and countries across the EU, and a shorter, more predictable assessment pathway gives sponsors another reason to consider the UK for conducting studies.
This is important because the impact of Phase I can extend beyond the first study in a development programme. Early experiences can help shape where sponsors build relationships with CROs and clinical sites, where later phase studies are placed and where further investment is made.
There is also a clear scientific benefit. Phase I studies generate important early human data on areas such as safety, tolerability, pharmacokinetics and pharmacodynamics. Getting suitable studies underway sooner means sponsors can begin generating that evidence sooner and use it to inform decisions about the next stage of development.
Importantly, the pilot is not about speeding up every Phase I study. It is focused on lower-risk studies in healthy volunteers where there is already satisfactory clinical safety information. The aim is to take a more proportionate approach to assessment while continuing to maintain the standards needed to protect participants.
Dr Shoona Vincent, Vice President of Clinical Science at MAC, explains:
“The 14-Day Phase I Pilot is more than a change to regulatory timelines. It sends a strong signal about the UK’s ambition to compete for early clinical development and to make the country an attractive place for global sponsors to conduct Phase I research.
Speed, predictability and regulatory clarity are all important when sponsors are deciding where to place studies. A faster pathway for appropriate, lower-risk trials has the potential to strengthen the UK’s position alongside other major early phase markets, while still keeping participant safety at the centre of the process.
Starting suitable studies sooner means generating early human data quicker, which can help inform decisions across the rest of the development programme. Phase I can also influence where later studies, relationships and investment develop, so attracting this research to the UK can have an impact well beyond the initial study.”
The pilot also has a wider significance for UK life sciences. Faster and more predictable regulatory pathways can help make the UK even more competitive internationally and support efforts to attract more clinical research and investment.
For sponsors, CROs and clinical sites, the immediate benefit is the potential for suitable Phase I studies to get underway sooner. But if the pilot is successful, the longer-term impact could be much broader, strengthening the UK’s position for early phase research and helping to bring more clinical development programmes to the country.
